Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer
about
Rapalogs in cancer prevention: anti-aging or anticancer?Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancerThe mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cellsRapamycin extends maximal lifespan in cancer-prone mice.Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes.Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.Translational advances regarding hereditary breast cancer syndromes.Selective anti-cancer agents as anti-aging drugsNCI's provocative questions on cancer: some answers to ignite discussion.Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions.Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.Rapamycin inhibits growth factor-induced cell cycle regulation in pancreatic beta cellsCurrent approaches and future directions in the treatment of HER2-positive breast cancer.Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.Effect of sirolimus on urinary bladder cancer T24 cell line.Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy.17β-Estradiol on the Expression of G-Protein Coupled Estrogen Receptor (GPER/GPR30) Mitophagy, and the PI3K/Akt Signaling Pathway in ATDC5 Chondrocytes In Vitro.
P2860
Q26866151-98E0A380-3636-4A8E-A608-7E3798F795AFQ27332151-63CE798F-F707-40E7-B138-5B7C1D5BAA8FQ33670472-3085D154-1BB3-4BB9-8106-D56E7B09F677Q33816255-DE5EAA6B-3C57-4A7C-A5E5-5B9168121291Q33849666-2A90721B-1514-439C-A7C8-222B6FC1D010Q34135475-AE4B5F31-7A2D-4885-8288-BEEDC3A2E52FQ34263162-61F3AFE4-8BF7-4E0B-AE95-9640534385EFQ34392470-977A33E2-2460-4B8A-85AB-F6655A075C87Q35764401-43C45AE8-3BE0-499A-A72C-A7637C5A6899Q36926148-242B33FA-8017-4C1D-9814-19527C77DC8EQ37076842-D2D46C80-CC6F-458A-A7C4-22AFEFBCFD98Q37259485-203C595C-F159-447E-A747-550C7153EC5DQ37330128-A55AE282-642C-4416-B447-20B3382FF6CAQ37456176-8C7264E1-28EA-4BE9-AF74-F6BBD457DF18Q39366450-AB278C86-088F-4DF1-901A-2FF276BEBBD5Q39898000-51736B1B-7BB3-4192-A1C5-E8B77122A994Q47099537-EEDABF9E-8989-47B6-A9A9-407B5438910EQ55240608-E777E21C-2D1E-4F2A-BFCF-9B94C48FA044
P2860
Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Rapamycin inhibits multiple st ...... of HER2-positive breast cancer
@en
type
label
Rapamycin inhibits multiple st ...... of HER2-positive breast cancer
@en
prefLabel
Rapamycin inhibits multiple st ...... of HER2-positive breast cancer
@en
P2093
P2860
P1476
Rapamycin inhibits multiple st ...... of HER2-positive breast cancer
@en
P2093
Darcie D Seachrist
John T Poirier
Melissa D Landis
Ruth A Keri
P2860
P304
P356
10.1158/1535-7163.MCT-07-0235
P577
2007-08-01T00:00:00Z